Emergent BioSolutions
Gaithersburg, Maryland, United States
About
Emergent BioSolutions is a defense prime contractor based in Gaithersburg, United States working in cbrn defense.
Emergent BioSolutions is a public health company that develops, manufactures and supplies medical countermeasures for national security and public health preparedness. Its portfolio includes vaccines, antitoxins and antivirals against biological threats such as anthrax, smallpox, mpox, botulism and Ebola, much of it procured by the U.S. government and supported by BARDA and NIAID. The company also sells commercial products for opioid overdose, including naloxone nasal spray, and runs medical education, research and charitable giving programmes. Its headquarters are in Gaithersburg, Maryland, with manufacturing sites in Lansing, Michigan, Winnipeg, Manitoba and Canton, Massachusetts, and offices in Plymouth Meeting, Washington DC, Toronto, Dublin and London.
Location
Company type
Focus areas
Languages
Products & capabilities
Defense domains
Supply-chain role
What they offer
Markets
Products
BioThrax
Anthrax vaccine
FDA-licensed anthrax vaccine, the first multi-year U.S. government contract product.
CYFENDUS
Anthrax vaccine
Anthrax vaccine developed under funding from BARDA and NIAID, FDA approved.
ACAM2000
Smallpox and mpox vaccine
Live smallpox vaccine acquired by Emergent.
TEMBEXA
Smallpox antiviral
Smallpox treatment acquired by Emergent.
BAT
Botulism antitoxin
Botulism antitoxin supported under U.S. biodefense contracts.
Anthrasil
Anthrax immune globulin
Anthrax treatment product in Emergent's countermeasure portfolio.
raxibacumab
Anthrax antitoxin
Monoclonal antibody for inhalational anthrax, acquired by Emergent.
